Physician profile
Robert C Karas
NPI 1679512248
$1,291.24
in general payments reported to CMS, 2019-2025
21 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $89.13 · 2021: $149 · 2022: $215 · 2023: $151 · 2024: $211 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $157.77 | 2019-2020 | |
| Gilead Sciences, INC. | $156.95 | 2020-2024 | Epclusa |
| Abbvie INC. | $150.67 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| Genentech USA, INC. | $86.33 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.52 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $74.19 | 2021-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.68 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $58.51 | 2022-2024 | Airsupra |
| Abbott Laboratories | $52.78 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $42.19 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $35.38 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $35.16 | 2023 | Veozah |
| Vanda Pharmaceuticals INC. | $34.11 | 2025 | Fanapt |
| Philips North America LLC | $32.07 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.75 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $21.07 | 2021 | |
| Corium, LLC | $19.50 | 2024 | Azstarys |
| Alkermes, INC. | $12.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.43 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Karas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.